NRIX Stock Forecast & Price Target

Nurix Therapeutics is viewed favorably because its lead asset bexobrutideg has shown encouraging efficacy and safety in CLL, supporting the company’s targeted protein degradation platform and its potential to extend into additional hematologic and autoimmune indications. The outlook is further strengthened by high-quality collaborations with Roche, SNY, GILD, and PFE, which validate the science, broaden development optionality, and help fund R&D, while pro forma cash of about $1.14B and 2Q26 cash of $443.5M suggest a solid runway. Near-term upside is also supported by multiple catalysts, including expected 2026 updates and the progression of STAT6 and IRAK4 programs, with the company still operating from a relatively modest ~$3B fully diluted market cap versus the potential of its pipeline.

Nurix Therapeutics is a clinical-stage biopharmaceutical company with no approved products, so its value depends heavily on a narrow pipeline and the eventual success of bexobrutideg, NX-1607, NX-2127, and NX-5948. The downside case is driven by the possibility that bexobrutideg fails to show durable efficacy or raises safety concerns, which could leave the shares closer to net cash with little pipeline value, while the company also faces meaningful development, data transparency, and dilution risks. Competition in STAT6 is intensifying, with several inhibitors already in the clinic and some facing delays or safety questions, but Nurix still carries execution risk because any setback in proof-of-concept, approval timing, or partner strategy would materially weaken the investment thesis.